First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA
4 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Read more
*Estimates of patients treated reflect global data since launch (Apr 2014-Mar 2023; US=59% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.
*Eligibility criteria and program maximums apply. Click here for full Terms and Conditions.
The safety profile for Otezla was studied in 7 clinical trials across mild to moderate and moderate to severe plaque psoriasis, ‡ and 6 clinical trials in active PsA 1,2,7-9
†Patients with moderate to severe plaque psoriasis in the ESTEEM clinical trials could be treated through 5 years. Patients with active PsA in the PALACE 1-4 trials could be treated through 5 years. ‡The 7 clinical trials for plaque psoriasis include ADVANCE, ESTEEM 1 & 2, SPROUT, STYLE, LIBERATE, and DISCREET.§The 6 clinical trials for active PsA include PALACE 1, PALACE 2, PALACE 3, PALACE 4, FOREMOST, and ACTIVE. **Estimates of patients treated reflect global data since launch (Apr 2014-March 2024; US=59% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
Inclusion on formulary does not imply superior clinical efficacy or safety.
††Covered includes Covered, Covered (PA/ST), Preferred and Preferred (PA/ST) as defined by Managed Markets Insights and Technology (MMIT) data. ‡‡Number of commercially insured plaque psoriasis lives provided is obtained from MMIT for health plans in the US. Data as of March 2024. §§This calculation excludes Department of Defense (DoD) TRICARE, Department of Veteran Affairs (VA), and Indian Health Service (IHS) government plans. ***Number of commercially insured plaque psoriasis and active psoriatic arthritis lives provided is obtained from MMIT for health plans in the US. Data as of June 2023.
BSA, body surface area; MOA, mechanism of action; PA, prior authorization; ST, step therapy; TB, tuberculosis.
Contraindications
Otezla® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulationWarnings and Precautions
Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapyContraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® is indicated for the treatment of:
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014. 4. Van Voorhees AS, Feldman SR, Lebwohl MG, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide. psoriasis.org/the-pocket-guide/ Accessed August 1, 2024. 5. Shafer PH, Parton A, Capone L, et al. Cell Signal. 2014;26(9):2016-2029. 6. Menter A, Gelfand JM, Connor C, et al. J Am Acad Dermatol. 2020;82:1445-86. 7. Kavanaugh A, Gladman DD, Edwards CJ, et al. Arthritis Res Ther. 2019;21(1):118. 8. Reich K, Gooderham M, Green L, et al. J Eur Acad Dermatol Venereol. 2017;31(3):507-517. 9. Nash P, Ohson K, Walsh J, et al; ACTIVE Investigators. Ann Rheum Dis. 2018;77(5):690-698. 10. Fiorillo L, Becker E, de Lucas R, et al. J Am Acad Dermatol. 2024;90(6):1232-1239.